Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690444 | 1.00 | TGFBR1 (0.59) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL6579582 | 1.00 | TGFBR1 (0.59) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL31571912 | 0.95 | TGFBR1 (0.61) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL31571914 | 0.93 | TGFBR1 (0.59) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL5013249 | 0.90 | FOLH1 (0.50) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL5013251 | 0.90 | FOLH1 (0.50) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL8376832 | 0.87 | TGFBR1 (0.46) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL1455722 | 0.86 | FOLH1 (0.58) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL1455716 | 0.86 | FOLH1 (0.58) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL31243301 | 0.84 | TGFBR1 (0.44) | TGFBR1FOLH1SLC6A5GSRCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096514-B | Polymerizable amino acid-based compounds and ophthalmic devices made therefrom | 强生视力健公司 | 2025-06-17 | — | — | CN | claimed |
| CN-119060329-B | Enzyme response polyamino acid, self-adaptive bionic mechanical gradient hydrogel and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2025-03-07 | — | — | CN | claimed |
| CN-119060329-A | Enzyme response polyamino acid, self-adaptive bionic mechanical gradient hydrogel and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-12-03 | — | — | CN | claimed |
| EP-4165015-B9 | AMINO ACID-BASED POLYMERIZABLE COMPOUNDS AND OPHTHALMIC DEVICES PREPARED THEREFROM | JOHNSON AND JOHNSON VISION CARE INC (US) | 2024-11-27 | — | — | EP | claimed |
| CN-115427746-B | Use of a coating composition to make a substrate frost resistant, composition and method therefor | 西恩斯科公司 | 2024-11-22 | — | — | CN | claimed |
| EP-4165015-B1 | AMINO ACID-BASED POLYMERIZABLE COMPOUNDS AND OPHTHALMIC DEVICES PREPARED THEREFROM | JOHNSON AND JOHNSON VISION CARE INC (US) | 2024-08-07 | — | — | EP | claimed |
| CN-118236297-A | Polyphenol moisturizing skin care lotion and preparation method thereof | 费米善(丽水)科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-114702700-B | Preparation method of anticoagulant filler for blood perfusion device | 江苏恰瑞生物科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| WO-2023116955-A1 | WATER-BORNE HYBRID VARNISH AND THE METHOD OF ITS PREPARATION | Centrum organické chemie s.r.o. (CZ) | 2023-06-29 | — | — | WO | claimed |
| US-20230183515-A1 | COATING COMPOSITION, USE AND METHODS FOR MAKING A SUBSTRATE FROST RESISTANT | SOLVAY SA (BE) | 2023-06-15 | — | — | US | claimed |
| WO-2011031453-A1 | METHOD OF CHEMICALLY MODIFYING THE INTERNAL REGION OF A HAIR SHAFT | THE PROCTER & GAMBLE COMPANY (US) | 2011-03-17 | — | — | WO | claimed |
| EP-2295029-A1 | Method of chemically modifying the internal region of a hair shaft | The Procter & Gamble Company (US) | 2011-03-16 | — | — | EP | claimed |
| US-20100003210-A1 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2010-01-07 | — | — | US | claimed |
| US-20090022681-A1 | Hair Care Composition | THE PROCTER & GAMBLE COMPANY | 2009-01-22 | — | — | US | claimed |
| WO-2008055482-A1 | CONTACT LENS MATERIAL | WOEHLK CONTACT-LINSEN GMBH (DE) | 2008-05-15 | — | — | WO | claimed |
| WO-2007127722-A2 | SURFACE-MODIFIED SUBSTRATE AND METHOD OF ITS PREPARATION | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-11-08 | — | — | WO | claimed |
| EP-1846010-A1 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION | Pola Chemical Industries Inc. (JP) | 2007-10-24 | — | — | EP | claimed |
| WO-2006067945-A1 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2006-06-29 | — | — | WO | claimed |
| EP-0225503-B1 | RESOLUTION SYSTEM | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-08-02 | — | — | EP | claimed |
| EP-0225503-A1 | Resolution system | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-06-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022681-A1 | Hair Care Composition | MTR, SUCLG1, MUC1 | TGFBR1 2595/4885FOLH1 2095/4885SLC6A5 4256/4885 |
| US-20100003210-A1 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION | CUTA, TSLP, NFKBIA | TGFBR1 1346/4885FOLH1 3951/4885SLC6A5 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.